Exciting News from Century Therapeutics
Century Therapeutics, Inc. (NASDAQ: IPSC), a pioneering biotechnology firm, is set to showcase its groundbreaking work in the field of cell therapies. At the forthcoming H.C. Wainwright 27th Annual Global Investment Conference, Brent Pfeiffenberger, Pharm.D., Chief Executive Officer, will spotlight the company's innovative approaches to treat autoimmune diseases and cancer using induced pluripotent stem cell (iPSC) technology. This conference will take place from September 9-10, where Century will connect with investors in New York City.
Investor Engagement and Presentation
Attendees of the conference will have the unique opportunity to meet and discuss with Century's leadership team. The company has planned a comprehensive presentation to discuss its current pipeline and development strategies. This presentation is critical as it not only highlights the scientific progress but also showcases the company’s dedication to advancing patient care through innovative therapies.
Webcast Details
The presentation can be accessed via an on-demand webcast starting at 7:00 a.m. ET on September 5. Interested parties can find more details on the Investors page of Century's official website. This is an excellent opportunity for stakeholders to gain deeper insight into the company’s advancements and future outlook.
About Century Therapeutics
Century Therapeutics is a clinical-stage biotechnology company that utilizes specialized knowledge in cellular reprogramming and genetic engineering to create novel cell therapies. Their iPSC-derived therapies are designed to tackle the complexities of autoimmune disorders and various cancers effectively. Their overarching commitment to developing off-the-shelf therapies seeks to enhance accessibility and improve patient outcomes in the healthcare sector.
Current Pipeline Highlights
Century’s diverse pipeline includes innovative treatments that leverage the unique properties of iPSCs. These therapies are designed to provide tangible benefits compared to traditional approaches. By integrating advancements in genetic engineering, Century aims to position itself at the forefront of biotechnology solutions tailored for serious health problems.
Company Contact Information
If you are looking for more details about Century Therapeutics or their projects, you can contact:
Century Therapeutics
Douglas Carr
Senior Vice President, Finance
investor.relations@centurytx.com
JPA Health
Sarah McCabe
smccabe@jpa.com
Frequently Asked Questions
What is the focus of Century Therapeutics?
Century Therapeutics is focused on developing iPSC-derived cell therapies for autoimmune diseases and cancer treatment.
When will the company present at the investment conference?
The company will present at the H.C. Wainwright 27th Annual Global Investment Conference on September 9-10.
How can I access the presentation?
The presentation will be available via a webcast starting September 5 on Century's Investor Relations webpage.
What are induced pluripotent stem cells (iPSCs)?
Induced pluripotent stem cells are genetically reprogrammed cells that have the capacity to differentiate into various cell types, providing unique therapeutic opportunities.
Who can I contact for more information?
You can contact Douglas Carr at Century Therapeutics for investor relations or reach out to Sarah McCabe at JPA Health for other inquiries.
